Please enable JavaScript.

Coggle requires JavaScript to display documents.

Profilaxia Hepatite B (ECIL-5 (2015) (HSCT (The risk of HBV reactivation…

- - - - All HBsAg-positive HSCT recipients should be treated indepen- dent of the presence or the level of HBV DNA (strong recommen- dation, moderate quality of evidence).
        Antiviral treatment should be conducted with entecavir or lamivudine (strong recommendation, moderate quality of evidence)
        Antiviral drugs should be started at least a week before the HSCT procedure and should be continued for at least 1 year (strong recommendation, moderate quality of evidence).
    - - ll anti-HBc-positive HSCT recipients should receive prophy- laxis with lamivudine, independent of the presence of HBV DNA, for a time period of at least 18 months (strong recommendation, moderate quality of evidence).
    - - All HBV-negative allo-HSCT recipients with anti-HBc-positive/ anti-HBs-positive or -negative (HBV DNA negative) donors should receive prophylaxis with lamivudine (weak recommendation, moderate quality of evidence). The lamivudine prophylaxis dura- tion is not defined (no recommendation, knowledge gap
- - - - In HBsAg-negative, anti-HBc positive subjects with moderate
        or low risk of HBV reactivation, pre-emptive ther-
        apy, not prophylaxis, is generally recommended.
        
        pre-emptive therapy is
        based upon monitoring HBsAg and/or HBV DNA every 1–
        3 months during and after immunosuppression, and starting
        ETV, TDF or TAF treatment in case of detectable HBV DNA or
        HBsAg seroreversion